Changfeng Pharmaceutical Doses First Subject in Phase I Trial for Lung Disease Drug ICF004

Changfeng Pharmaceutical (02652) announced it has enrolled and administered the first dose to a healthy volunteer in its Phase I clinical trial for ICF004, an investigational treatment for interstitial lung disease (ILD). The milestone, disclosed in a company filing, marks the transition of the drug candidate into the human dosing stage of its clinical development.

Trial and Drug Candidate Details

ICF004 is a Class 1 chemical drug formulated as a dry powder inhaler. It is being developed to treat interstitial lung disease, a group of disorders that cause progressive scarring of lung tissue. The company noted an unmet clinical need for patients with certain forms of ILD, including idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF), which can lead to a steady decline in lung function.

The inhaled delivery method is designed to send the drug directly to the lungs. This approach aims to increase local drug exposure in the target organ while potentially reducing systemic, or whole-body, exposure and associated side effects.

Background and Previous Studies

Prior to initiating this formal Phase I trial, Changfeng conducted investigator-initiated studies to gather preliminary data. An initial study in healthy volunteers assessed the safety and pharmacokinetics of a single dose of an atomized solution of ICF004.

Ad

• According to the company, preliminary results from that study showed the drug was generally well-tolerated within the tested dose range, with no serious adverse events reported as of the data cutoff date.

A subsequent study in ILD patients was conducted after optimizing the drug's formulation. The company stated that preliminary safety and pharmacokinetic observations from this study were consistent with the intended goal of enhancing local lung exposure while lowering systemic levels.

Strategic Importance

Completing the first dosing in this registered Phase I trial represents a key step forward in the clinical development of ICF004. Changfeng Pharmaceutical stated that the progress will also contribute to the company's experience in the research, development, and clinical translation of complex inhalation formulations and pulmonary drug delivery systems.